Advanced Drug Metabolism
MEDCH 527
Winter Quarter 2013

“Safety Considerations in Drug Development”

Thomas A. Baillie
School of Pharmacy, UW

tbaillie@uw.edu
Outline

• **Background**
  – Toxicity as a major source of attrition in drug development
  – Toxicity-related drug withdrawals
  – Toxicity studies in drug development

• **Metabolism-dependent drug toxicities**
  – Cardiovascular toxicity ($QT_c$ effects) caused by drug interactions
  – Liver injury (chemically reactive drug metabolites)

• **Stable drug metabolites (“MIST”)**
  – FDA and ICH* Guidances
  – Species differences in drug metabolism & toxicity

*ICH = International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
Reasons for Termination of Drug Candidates in Development (1964 - 1985)

- Human PK (39%)
- Clinical Efficacy (29%)
- Animal Toxicity (11%)
- Human AEs (10%)
- Improved Candidate (2%)
- Financial (1%)
- Commercial (6%)

Reasons for Termination of Drug Candidates in Development (2000)

- Human PK (8%)
- Clinical Efficacy (25%)
- Animal Toxicity (20%)
- Human AEs (11%)
- Commercial (20%)
- Financial (8%)
- Formulation (3%)
- Other (5%)

Target Organ Contributions to Drug Withdrawals

FIGURE 1
Summary of target organ contributions to drug withdrawals 1975–2007. Data were compiled from reviews [8–10] and CDER Reports to the Nation [11] as well as the CDER website. Target organs were identified on the basis of the reasons for withdrawal as noted in the references.

Widely Accepted That Attrition Must Occur Earlier!

• Given that attrition rates remain high, it is critical that only the very best candidates from Discovery / Lead Optimization efforts are taken forward into development.

• The role of scientists engaged in drug discovery has expanded in recent years such that it is now important to consider many issues beyond organic synthesis, pharmacology, etc, notably:
  – Drug Metabolism and Pharmacokinetics (DMPK)
  – Preclinical Toxicology

• Challenges in Drug Discovery
  – Minimizing potential for toxicity (esp. cardiovascular and liver toxicity)
  – “Dialing-out” drug-drug interaction potential
  – Dealing prospectively with reactive drug metabolite issues
  – Addressing potential issues with stable drug metabolites (“MIST”)
The principal barrier to bringing a continuous stream of innovation to the market place is that converting a chemical with interesting biological properties into a drug involves solving multiple complex issues “simultaneously” (in a single molecule).
From Sequential to Parallel Data Acquisition
A Paradigm Shift in Drug Discovery


ADME = Absorption, Distribution, Metabolism, and Excretion
The Drug Discovery / Development Pipeline
Preclinical Toxicity Studies in Support of Drug Development

- **Mutagenicity** - Ames, chromosomal aberration
- **hERG Binding** - indicative of QTc prolongation
- **General Toxicology** - rodent (rat or mouse) and non-rodent (dog or monkey)
  - Single doses to evaluate effects of high acute exposure (significant tox or lethality) and maximum tolerated dose (MTD)
  - Multiple doses at sub-lethal levels to assess sub-acute tox profile and define “no adverse effect level” (NOAEL)
  - >2-Week multiple dose data needed to support clinical trials up to 2 weeks in duration
  - *In vivo* studies incorporate toxicokinetic (TK) assays to assess exposure ($C_{\text{max}}$ and AUC) to parent (and abundant circulating metabolites)

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/default.htm
Preclinical Toxicity Studies in Support of Drug Development (Cont’d)

- **Safety Pharmacology**
  - *In vitro*: panel of receptor binding assays
  - *In vivo*: battery of studies to assess effects on CV, CNS, GI, and respiratory systems

- **Reproductive Toxicity**
  - Needed prior to enrollment of women of child-bearing potential

- **Carcinogenicity**
  - 2-Year bioassay in rats and mice (starts ~4 years prior to anticipated filing date)

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/default.htm
Clinical Safety Studies in Support of Drug Development

**Phase I (healthy volunteers)**
- Single ascending dose (SAD) for safety, tolerability, and PK
  - Starting dose selected to give ~100-fold lower AUC than NOAEL in most sensitive animal species
- Multiple ascending dose (MAD) – duration not to exceed that of longest animal studies
  - Detailed analysis of side-effect profile; circulating metabolites, drug interaction studies, etc

**Phase II and III (patients)**
- Long-term safety and efficacy studies that form the basis of regulatory filing (NDA)

**Postmarketing**
- Pharmacovigilence (adverse event reporting)
Toxicity Due to Drug-Drug Interactions at the Level of P450 Inhibition
P450 Inhibitors that Have Caused Life-Threatening DDIs

Ketoconazole
Competitive IC$_{50}$ <0.1µM for CYP3A
Warnings for serious DDIs

Mibefradil
Withdrawn in 1998 due to DDIs (QTc prolongation)
Competitive IC$_{50}$ for CYP3A <1µM
Mechanism-based CYP3A4/5 inhibitor (partition ratio 1.7)

http://www.fda.gov/cder/drug/druginteractions
Metabolism by P450 Enzymes – A Key Determinant of Drug Clearance

Figure 1 | Routes of elimination of the top 200 most prescribed drugs in 2002. Metabolism represents the listed clearance mechanism for ~73% of the top 200 drugs. Of the drugs cleared via metabolism, about three-quarters are metabolized by members of the cytochrome P450 (CYP) superfamily. For the CYP-mediated clearance mechanisms, the majority of drug oxidations (46%) were carried out by members of the CYP3A family; followed by 16% by CYP2C9; 12% for both CYP2C19 and CYP2D6; 9% for members of the CYP1A family; and 2% for both CYP2B6 and CYP2E1 (REF: 9). UGT, uridine diphosphate glucuronyl transferase.

Cardiovascular Toxicity: Drug-Drug Interactions Leading to QTc Prolongation

Inhibition of $I_{Kr}$ channel due to drug binding to hERG ($\alpha$-subunit) can produce delayed ventricular polarization (QTc interval prolongation).

In extreme cases, QTc prolongation leads to life-threatening ventricular fibrillation (Torsades de Pointes).
**hERG Binding and QTc Prolongation**

- Adverse cardiovascular effects, often associated with inhibition of hERG (α-subunit of the I_{Kr} potassium channel) leading to QTc prolongation, represent a major source of attrition in drug discovery.

- Drug withdrawals due to QTc effects:
  

- While the parent compound normally is the culprit, drug-drug interactions (DDIs) that result in **reduced drug clearance** may greatly exacerbate this type of toxicity.

- **Potent inhibitors of CYP3A4** have been most frequently implicated in these DDIs, e.g. ketoconazole (warning label), mibefradil (withdrawn)
Torsades de Pointes Occurring in Association With Terfenadine Use

Brian P. Monahan, MD; Clifford L. Ferguson, MD; Eugene S. Killeavy, MD; Bruce K. Lloyd, MD; James Troy; Louis R. Cantilena, Jr, MD, PhD

Torsades de pointes is a form of polymorphic ventricular tachycardia that is associated with prolongation of the QT interval. Although found in many clinical settings, torsades de pointes is most often drug induced. This report describes the first association (exclusive of drug overdose) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone. Measured serum concentrations of terfenadine and its main metabolite showed excessive levels of parent terfenadine and proportionately reduced concentrations of metabolite, suggesting inhibition of terfenadine metabolism. We believe that a drug interaction between terfenadine and ketoconazole resulted in the elevated terfenadine levels in plasma and in the cardiotoxicity previously seen only in cases of terfenadine overdose.

(JAMA. 1990;264:2788-2790)
Terfenadine:
- Potent inhibitor of hERG channel
- CYP3A4 inhibitors raise terfenadine levels and cause QTc prolongation
- Introduced as Seldane (Marion Merrell Dow) in 1985, withdrawn in 1997

Fexofenadine:
- An active metabolite of terfenadine
- Contributes to H1 antagonism, but not to hERG inhibition
- Not subject to metabolism by CYP3A4 inhibitors (minimizes DDI potential)
- Marketed as Allegra (Aventis) in 1996
Paying Attention to Drug-P450 Interaction Potential

Mibefradil (Posicor®)

Mibefradil - Calcium channel blocker, approved as an antihypertensive in 1997

- Exhibited non-linear PK due to self-inactivation of CYP3A4
- Highly potent CYP3A4 inactivator in vitro ($k_{\text{inact}} = 0.5 \text{ min}^{-1}$, $K_I = 2 \mu\text{M}$)
- Caused serious clinical AEs when dosed with CYP3A4 substrates (eg simvastatin, atorvastatin)
- Fatal cases of DDIs leading to rhabdomyolysis (statins) and QTc prolongation
- Voluntarily withdrawn by the manufacturer in 1998

**hERG Binding – Current Status**

- *In vitro* and *in vivo* screens for CV effects established.

- Regulatory guidance for nonclinical (ICH S7B) and clinical (ICH E14) testing strategies published in 2005.

- Safety margin based on ratio of:
  \[(\text{hERG IC}_{50} / C_{\text{max}}) \text{ or } (\text{NOAEL} / C_{\text{max}})\]
  at expected top dose should be >30, and preferably >100.

- Med Chem strategies to minimize QTc effects include:
  - Formation of zwitterions (e.g. terfenedine to fexofenadine)
  - Modulation of LogP
  - Attenuation of pKa
  - Computational (QSAR models)

*Curr. Topics Med Chem.*, 8(13), 2008
A P450 Inhibitor that is Therapeutically Valuable

Ritonavir (HIV Protease Inhibitor)

Potent mechanism-based CYP3A4 inhibitor
Mechanism of CYP inhibition likely associated with thiazole ring(s)
Used clinically to "boost" exposure of other anti-HIV agents

Other HIV protease inhibitors that lack a thiazole functionality do not serve as mechanism-based inhibitors of CYP3A4

T. Koudriakova et al., Drug Metab. Dispos., 26, 552-561 (1998)
Drug-Induced Liver Toxicity
Drug-Induced Liver Toxicity

Several forms, including:

- Predictable, dose-dependent toxicities (animal model, clear dose-response relationship, etc)
- “Idiosyncratic” toxicities (rare, not predictable, no animal model)
- Occur only after prolonged dosing (carcinogenicity, teratology)

- Evidence suggests that, in some cases, reactive metabolites may play a causative role in each of the above forms of liver toxicity
- Idiosyncratic toxicities of greatest concern in drug development

Bioactivation and Liver Toxicity

• A wide range of therapeutic agents have been withdrawn from use due to an unacceptably high incidence of hepatotoxicity:

  Aclofenac, alpidem, amodiaquine, amineptine, benoxaprofen, bromfenac, ibufenac, iproniazid, nefazodone, nomifensine, sudoxicam, tienilic acid, tolrestat, troglitazone, trovafloxacin, zileuton, zomepirac

• Many other marketed drugs have warnings for a risk of liver toxicity, or severe restrictions in their use

• For most of these agents, bioactivation to reactive metabolites has been demonstrated to occur either in vitro (human hepatic tissue) or in vivo (characterization of downstream stable metabolites)

• High dose drugs (>100mg/day) tend to be the ones which most frequently cause liver toxicity

Bioactivation and Liver Toxicity
Acetaminophen

Acetaminophen (APAP)

NAPQI
(Quinone imine)

GSH

APAP-GSH

APAP Sulfate
APAP Glucuronide

Covalent Binding to Proteins
Oxidative Stress
Depletion of GSH Pools

Liver Toxicity

I. M. Copple et al., Hepatology, 48, 1292-1301 (2008)
In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs

Richard A. Thompson,*† Emre M. Isin,† Yan Li,‡ Lars Weidolf,§ Ken Page,§ Ian Wilson,§ Steve Swallow,‖ Brian Middleton,⁷ Simone Stahl,‖ Alison J. Foster,‖ Hugues Dolgos,‖ Richard Weaver,‖ and J. Gerry Kenna‖

†DMPK Innovative Medicine, AstraZeneca, Mölndal, 431 83, Sweden
‡Discovery DMPK, AstraZeneca, Wilmington, Delaware, United States
§DMPK Innovative Medicine, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
‖Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
⁷Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
*Discovery DMPK, AstraZeneca, Loughborough, Leicestershire LE11 1SR, United Kingdom

Supporting Information

ABSTRACT: Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clinically significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling. IADRs arise from both drug and patient-related mechanisms and risk factors. Drug-related risk factors, resulting from parent compound or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compound disposition, and/or immune activation. In the current study, we evaluate an in vitro approach, which explored both cellular effects and coherent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans. The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigens-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance associated protein 2, Mrp2. In addition, the CVB Burden was estimated by determining the CVB of radiolabeled compound to human hepatocytes and factoring in both the maximum prescribed daily dose and the fraction of metabolism leading to CVB. Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.
Safety Evaluation of Stable Drug Metabolites

Metabolites in Safety Testing ("MIST")
Metabolites in Safety Testing ("MIST")

• Central Question
  “Are human metabolites of a drug candidate, as well as the parent compound, adequately evaluated for safety during preclinical toxicology studies?”

• PhRMA “White Paper” on best practices published in 2002

  http://www.fda.gov/cder/guidance/index.htm

• Numerous commentaries on MIST published during past 10 years
  eg special issue of *Chem. Res. Toxicol.*, 22(2), February, 2009, and references therein

Key concern for industry: Resource and time implications for development
**FDA Guidance on “Safety Testing of Drug Metabolites”**

- Applies only to small molecule non-biologic drug products

- Excludes:
  - anti-cancer agents
  - drug conjugates (other than acylglucuronides)
  - reactive intermediates

- Focuses on:
  - *stable* metabolites circulating in human plasma
  - unique or “disproportionate” metabolites in humans

- Key recommendations:
  - a metabolite whose $\text{AUC}_p$ at steady-state is <10% that of parent needs no further study
  - if $\text{AUC}_p$ is >10% of parent, “coverage” (i.e. exposure margin ≥1) needs to be demonstrated in at least one tox species
  - otherwise, human metabolite is “disproportionate” and may require testing

- Types of toxicology studies that may be required:
  - general tox (3 months), genotoxicity, embryo-fetal development tox, carcinogenicity

http://www.fda.gov/cder/guidance/index.htm
ICH Topic M3 (R2)
Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

• Key recommendations:

  - Only those human metabolites observed at levels >10% of total drug-related exposure require nonclinical characterization, if they circulate at “significantly greater” levels in humans than the maximum exposure in animal toxicology studies

  - For drugs dosed at <10mg / day, a larger % of the total drug-related material might be appropriate before safety testing is needed

  - Some metabolites do not warrant testing (eg “most GSH conjugates”)

  - “Unique human metabolites” should be considered on a case-by-case basis

http://www.emea.europa.eu
Practical Issues with MIST Guidances

• **FDA Guidance**
  - How to assess those metabolites in human plasma that circulate at >10% AUC of parent drug under **steady-state** dosing conditions?
  - Multiple ascending dose (safety/tolerability) study with “cold” drug and LC-MS/MS analysis? Availability of validated assay for metabolite(s)?

• **ICH Guidance**
  - How to assess “**total drug-related exposure**” in plasma?
  - Radioactive dose (with required GMP synthesis, dosimetry, etc)?

As of January, 2010, where the FDA and ICH guidances differ, the ICH guidance supersedes the FDA guidance.

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/default.htm

Species Differences in Drug Metabolism

**c-MET Inhibitor SGX 523**

Urinary metabolite profiles

**Solubility in monkey urine (pH 8.4):**
SGX 523 – 13µg/ml  
M11 – 0.37µg/ml

Conclusions

• Drug metabolism now plays an integral role in the safety evaluation of new drug candidates and their circulating metabolites

• Both stable and chemically reactive drug metabolites need to be taken into consideration, and the identities of likely human metabolites established, at the lead optimization stage of preclinical development

• Preliminary studies on circulating human metabolites need to be conducted during early clinical development (Phase I / II) such that “disproportionate” metabolites can be identified and addressed preclinically

• The implementation of regulatory guidances from the FDA and ICH requires that a detailed understanding of the metabolic fate of a new drug candidate be established, both in humans and in the animal species used for toxicology studies, prior to the start of large-scale (Phase III) clinical trials